News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,971 Results
Type
Article (13951)
Company Profile (304)
Press Release (247716)
Section
Business (79429)
Career Advice (151)
Deals (13204)
Drug Delivery (34)
Drug Development (50335)
Employer Resources (31)
FDA (5682)
Job Trends (5117)
News (144222)
Policy (10021)
Tag
Academia (901)
Alliances (21547)
Alzheimer's disease (760)
Approvals (5665)
Artificial intelligence (69)
Bankruptcy (97)
Best Places to Work (4523)
Biotechnology (249)
Breast cancer (110)
Cancer (894)
Cardiovascular disease (71)
Career advice (132)
CAR-T (73)
Cell therapy (217)
Clinical research (40153)
Collaboration (311)
Compensation (129)
COVID-19 (1008)
C-suite (79)
Cystic fibrosis (67)
Data (986)
Diabetes (87)
Diagnostics (1214)
Drug discovery (57)
Earnings (29057)
Events (47223)
Executive appointments (249)
FDA (6055)
Funding (310)
Gene editing (63)
Gene therapy (163)
GLP-1 (311)
Government (1065)
Healthcare (6595)
Infectious disease (1046)
Inflammatory bowel disease (98)
IPO (7213)
Job creations (859)
Job search strategy (127)
Layoffs (188)
Legal (1376)
Lung cancer (131)
Lymphoma (62)
Manufacturing (87)
Medical device (2560)
Medtech (2561)
Mergers & acquisitions (6131)
Metabolic disorders (262)
Neuroscience (1006)
NextGen Class of 2024 (2004)
Non-profit (847)
Northern California (1096)
Obesity (142)
Opinion (91)
Parkinson's disease (78)
Patents (63)
People (25112)
Phase I (14158)
Phase II (18670)
Phase III (11821)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (204)
Real estate (1410)
Regulatory (8291)
Research institute (932)
Southern California (983)
Startups (1964)
United States (8717)
Vaccines (165)
Weight loss (84)
Date
Last 7 days (219)
Last 30 days (1394)
Last 365 days (20596)
2024 (20528)
2023 (22442)
2022 (26855)
2021 (27839)
2020 (23395)
2019 (16234)
2018 (11741)
2017 (13755)
2016 (11840)
2015 (14363)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16930)
Australia (2856)
California (2488)
Canada (817)
China (206)
Colorado (93)
Connecticut (104)
Europe (36467)
Florida (273)
Georgia (71)
Illinois (154)
Indiana (61)
Maryland (336)
Massachusetts (1961)
Michigan (58)
Minnesota (101)
New Jersey (635)
New York (692)
North Carolina (420)
Northern California (1096)
Ohio (82)
Pennsylvania (478)
South America (207)
Southern California (983)
Texas (282)
Washington State (249)
261,971 Results for "acuitas therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Aldevron Announces Strategic Partnership with Acuitas Therapeutics
Aldevron, a leading global manufacturer of DNA, RNA, and proteins used in cell and gene therapies and vaccine development, today announced it has entered a strategic partnership with Acuitas Therapeutics, Inc., a private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNPs).
May 13, 2024
·
4 min read
Business
BIOVECTRA Signs Service Agreement With Acuitas Therapeutics for Unique Lipid Nanoparticle (LNP) Delivery System Used in Manufacturing mRNA-Based Therapies
BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ best-in-class LNP technology platform for manufacturing mRNA-based therapeutics.
October 5, 2023
·
4 min read
Business
Bayer Strengthens Gene Therapy Portfolio With Lipid Nanoparticle Technology From Acuitas Therapeutics
Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle delivery systems for molecular therapeutics.
June 6, 2023
·
5 min read
Business
IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System
IMUNON, Inc.(NASDAQ: IMNN) and Acuitas Therapeutics, a private biotechnology company focused on the development of delivery systems for nucleic acid vaccines and therapeutics based on lipid nanoparticles (LNP), today announced the signing of an agreement to evaluate the combination of IMUNON’s PLACCINE nucleic acid vaccine constructs formulated with Acuitas’ proprietary lipid delivery technology.
November 10, 2022
·
7 min read
Business
GC Biopharma Concludes Agreement With Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
GC Biopharma and Acuitas Therapeutics announced that they have entered into a Development and Option agreement for Acuitas’ LNP technology.
April 28, 2022
·
2 min read
Business
Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases
Arbor Biotechnologies today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles (LNP).
August 25, 2022
·
3 min read
Business
Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans
Myeloid Therapeutics, Inc. (“Myeloid” or the “Company”), today announced that it has entered into an agreement with Acuitas Therapeutics (“Acuitas”), a global leader in developing LNP delivery systems that enable mRNA-based therapeutics.
May 19, 2022
·
4 min read
Business
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
Pfizer Inc. and Acuitas Therapeutics announced they have entered into a Development and Option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development.
January 10, 2022
·
6 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
·
2 min read
·
Tristan Manalac
1 of 26,198
Next